Assessing generalisability in model-based economic evaluation studies: A structured review in osteoporosis

PharmacoEconomics

Volumn 24, Issue 12, 2006, Pages 1181-1197

  Urdahl, Hege ^a   Manca, Andrea ^b   Sculpher, Mark J ^b  

^a Merck Sharp & Dohme Limited   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DECISION MAKING; ECONOMIC ASPECT; FRACTURE; HUMAN; MEDICAL LITERATURE; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY ANALYSIS;

COSTS AND COST ANALYSIS; DECISION MAKING, ORGANIZATIONAL; ENDPOINT DETERMINATION; HUMANS; MODELS, ECONOMIC; OSTEOPOROSIS;

EID: 33845431345     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624120-00004     Document Type: Review

References (44)

1. Hjelmgren J, Berggren F, Andersson F. Health economic guidelines: similarities, differences and some implications. Value Health 2001; 4: 225-50
2. Weinstein MC, Fineberg HV. Clinical decision analysis. Philadelphia (PA); WB Saunders Company, 1980
3. Hunink M, Glaziou P, Siegel J, et al. Decision making in health and medicine: integrating evidence and values. Cambridge: Cambridge University Press, 2001
4. Sculpher MJ, Claxton K, Akerhurst R. It's just evaluation for decision making: recent developments in, and challenges for, cost-effectiveness research. In: Smith PC, Ginnelly L, Sculpher MJ, editors. Health policy and economics: opportunities and challenges. Maidenhead: Oxford University Press, 2005: 8-41
5. Willke RJ, Glick HA, Polsky D, et al. Estimating country-specific cost-effectiveness from multinational clinical trials. Health Econ 1998; 7: 481-93
6. Willan AR, Pinto EM, O'Brien BJ, et al. Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis. Health Econ 2005; 14: 327-38
7. Thompson SG, Nixon R, Grieve R. Addressing the issues that arise in multicentre cost data, with application to a multinational study. J Health Econ 2006; 25 (6): 1015-28
8. Pinto EM, Willan AR, O'Brien BJ. Cost-effectiveness analysis for multinational clinical trials. Stat Med 2005; 24: 1965-82
9. Manca A, Rice N, Sculpher MJ, et al. Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. Health Econ 2005; 14 (5): 471-85
10. Manca A, Willan AR. 'Lost in translation': accounting for between-country differences in the analysis of multinational cost effectiveness data. Pharmacoeconomics 2006; 24 (11): 1101-19
11. Koopmanschap MA, Touw KCR, Rutten FFH. Analysis of costs and cost-effectiveness in multinational trials. Health Policy 2001; 58 (2): 175-86
12. Grieve R, Nixon R, Thompson SG, et al. Using multilevel models for assessing the variability of multinational resource use and cost data. Health Econ 2005; 14 (2): 185-96
13. Coyle D, Cranney A, Lee KM, et al. Cost-effectiveness of nasal calcitonin in postmenopausal women: using Cochrane collaboration methods for meta-analysis in economic evaluation. Pharmacoeconomics 2001; 19: 565-75
14. Sculpher MJ, Torgerson D, Goeree R, et al. A critical structured review of economic evaluations of interventions for the prevention and treatment of osteoporosis. Centre for Health Economics discussion paper no. 169. York: University of York, CHE, 1999
15. Sculpher MJ, Pang FS, Manca A, et al. Generalisability in economic evaluation studies in health care: a review and case-studies. Health Technol Assess 2004; 8 (49): 1-206
16. Royal College of Physicians of London. Osteoporosis. Clinical guidelines for prevention and treatment. London: Royal College of Physicians of London, 1999
17. Office of Technology Assessment (OTA) US Congress. Effectiveness and costs of osteoporosis screening and hormone replacement therapy, Vol. I: cost effectiveness analysis. (OTA-BP-H-160). Washington DC: US Government Printing Office, 1995
18. French F, Torgerson DJ, Porter RW. Overestimation of cost savings in prevention of osteoporosis [letter]. BMJ 1994; 308: 138
19. Ankjaer-Jensen A, Johnell O. Prevention of osteoporosis: cost effectiveness of different pharmaceutical treatments. Osteopor Int 1996; 6: 265-75
20. Revicki DA, Frank L. Pharmacoeconomic evaluation in the real world: effectiveness versus efficacy studies. Pharmacoeconomics 1999; 15 (5): 423-34
21. Bombardier C, Maetzel A. Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? Ann Rheum Dis 1999; 58: 182-5
22. Hughes DA, Bagust A, Haycox A, et al. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 2001; 10: 601-15
23. Geelhoed E, Harris A, Prince R. Cost-effectiveness analysis of hormone replacement therapy and lifestyle intervention for hip fracture. Aust J Pub Health 1994; 18 (2): 153-60
24. Tosteson A, Rosenthal D, Melton L, et al. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densiometry and hormone replacement therapy. Ann Intern Med 1990; 113 (8): 598-603
25. Tosteson A, Weinstein M. Cost-effectiveness of hormone replacement therapy after the menopause. Baillieres Clin Obstet Gynaecol 1991; 5: 943-59
26. Francis R, Anderson F, Torgerson D. A comparison of the effectiveness and cost of treatment for vertebral fractures in women. Br J Rheumatol 1995; 34: 1167-71
27. Torgerson D, Reid D. Osteoporosis prevention through screening: will it be cost effective? Baillieres Clin Rheumatol 1993; 7 (3): 603-22
28. Torgerson D, Kanis J. Cost effectiveness of preventing hip fractures in the elderly population using vitamin D and calcium. Q J Med 1995; 88: 135-9
29. Visentin A, Ciravegna R, Fabris F. The cost per avoided hip fracture by osteoporosis treatment in Italy. Maturitas 1997; 26: 185-92
30. Cheung AP, Wren BG. A cost-effectiveness analysis of hormone replacement therapy in the menopause. Med J Aust 1992; 156: 312-6
31. Daly E, Roche M, Barlow D, et al. HRT: an analysis of benefits, risks and costs. Br Med Bull 1992; 48 (2): 368-400
32. Daly E, Vessey M, Barlow A, et al. Hormone replacement therapy in a risk-benefit perspective. Maturitas 1996; 23: 247-59
33. Garton M, Cooper C, Reid D. Perimenopausal bone density screening -will it help prevent osteoporosis? Maturitas 1997; 26: 35-43
34. Weinstein M. Estrogen use in postmenopausal women: costs, risks and benefits. N Engl J Med 1980; 303: 308-16
35. Weinstein M, Schiff I. Cost-effectiveness of hormone replacement therapy in the menopause. Obstet Gynaecol Surv 1983; 38: 445-54
36. Rosner A, Grinna D, Torrance G, et al. Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Pharmacoeconomics 1998; 14 (5): 559-73
37. Weinstein M, Tosteson A. Cost-effectiveness of hormone replacement. Ann N Y Acad Sci 1990; 592: 162-73
38. Caro JJ, Huybrechts KF, De Backer G, et al. Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium. Acta Cardiol 2000; 55 (4): 239-46
39. Palmer S, Sculpher M, Philips Z, et al. Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIa antagonists in the UK National Health Service? Int J Cardiol 2005; 100: 229-40
40. Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. Pharmacoeconomics 2000; 17 (5): 461-77
41. International Society for Pharmacoeconomics and Outcomes Research. Principles for good practice in decision analytic modelling in health care evaluation: a statement from the ISPOR Taskforce on Modelling [online]. Available from URL: http://www.ispor.org/workpaper/healthscience/TFModeling.pdf [Accessed 2006 Sep 20]
42. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: National Institute for Health and Clinical Excellence (NICE), 2004
43. Briggs AH, Goeree R, Blackhouse G, et al. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002; 22: 290-308
44. Drummond MF, Manca A, Sculpher MJ. Increasing the generalisability of economic evaluations. Recommendations for the design, analysis and reporting of studies. Int J Technol Assess Health Care 2005; 21 (2): 165-71